GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017
March 01 2017 - 8:52PM
Business Wire
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that
pre-clinical research demonstrating the potential of two of its
drug candidates, GMI-1271 and GMI-1359, against multiple myeloma
will be shared via an oral presentation at the American Association
for Cancer Research (AACR) Annual Meeting 2017 in Washington, DC.
The company and its collaborators at Washington University in St.
Louis will highlight data on GMI-1271, an antagonist of E-selectin,
and GMI-1359, a dual antagonist of E-selectin and CXCR4, showing
anti-cancer activity in preclinical models of multiple myeloma.
The research demonstrated that:
- In cell culture, GMI-1271 and, to a
greater extent GMI-1359, reduced multiple myeloma cell adhesion to
stromal cells and inhibited chemotaxis of multiple myeloma cells
toward conditioned media.
- The presence of GMI-1271 or GMI-1359
reduced stroma-induced drug resistance of multiple myeloma cells to
carfilzomib and lenalidomide. In a preclinical model of multiple
myeloma, combination therapy of GMI-1271 and lenalidomide
profoundly delayed tumor growth.
- Combination therapy of carfilzomib with
GMI-1271 or GMI-1359 prolonged survival of mice with multiple
myeloma over treatment with carfilzomib alone.
“Our results show a strong effect on cancer cells in combination
with chemotherapy and importantly, are supportive of our ongoing
Phase 1 clinical studies in multiple myeloma of GMI-1271 as well as
our study of GMI-1359 in multiple cancers,” said John Magnani,
Ph.D., GlycoMimetics Senior Vice President and Chief Scientific
Officer. “These results complement data from other preclinical
studies and continue to build the rationale for our on-going
clinical programs with both compounds.”
Details of the AACR presentation include:
Abstract #5005—Muz, B.B., et al. “Inhibition of
E-Selectin or E-selectin together with CXCR4 re-sensitizes multiple
myeloma to treatment.” Tuesday, April 4, 3:00-5:00 p.m. ET.
The AACR Annual Meeting 2017 takes place from April 1 to 5, at
the Walter E. Washington Convention Center. Meeting abstracts are
available at AACR’s website.
GMI-1271 is currently being evaluated in an ongoing Phase 1/2
clinical trial as a potential treatment for acute myeloid leukemia
(AML) and in a Phase 1 clinical trial in multiple
myeloma. GMI-1359 is now in a Phase 1 clinical trial.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on cancer and sickle cell disease. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin
antagonist, is being evaluated in an ongoing Phase 1/2 clinical
trial as a potential treatment for AML and in a Phase 1 clinical
trial in multiple myeloma. GlycoMimetics has also
recently initiated a clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics’ planned activities with respect to the clinical
development of its drug candidates, GMI-1271 and GMI-1359. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the availability and timing of data from ongoing
clinical trials, the uncertainties inherent in the initiation of
future clinical trials, whether interim results from a clinical
trial will be predictive of the final results of the trial or
results of early clinical trials will be indicative of the results
of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics’ foreseeable
and unforeseeable operating expenses and capital expenditure
requirements, other matters that could affect the availability or
commercial potential of GlycoMimetics’ drug candidates and other
factors discussed in the “Risk Factors” section of GlycoMimetics’
Annual Report on Form 10-K that was filed with the U.S. Securities
and Exchange Commission on February 29, 2016, and other filings
GlycoMimetics makes with the Securities and Exchange Commission
from time to time. In addition, the forward-looking statements
included in this press release represent GlycoMimetics’ views as of
the date hereof. GlycoMimetics anticipates that subsequent events
and developments may cause its views to change. However, while
GlycoMimetics may elect to update these forward-looking statements
at some point in the future, GlycoMimetics specifically disclaims
any obligation to do so, except as may be required by law. These
forward-looking statements should not be relied upon as
representing GlycoMimetics’ views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170301006700/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2024 to May 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From May 2023 to May 2024